IFR 100 and IFR 110 for Multiple Sclerosis (MS)

IFR 100  (CE mark, IL approved) and IFR 110 (double blood tests, still under post licensing development)  – can identify Multiple Sclerosis (MS) patients designated as responders prior to IFN β treatments (such as Avonex, Rebif, Betaseron,) or treatments. The  MS is an inflammatory degenerative disease  which  destroy  nerve cells insulating cover (myelin) in the brain and spinal cord. MS patients may receive up to 3 years treatment before a decision is taken (using MRI, number of relapses and EDSS) regarding their responsiveness. Genefron companion diagnostic kit can predict the patient response before a treatment has been initiated.

 

Comments are closed.